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Abstract 1 
An allergic reaction is rapidly generated when allergens bind and crosslink immunoglobulin E 2 
bound to its receptor FcεRI on effector cells, resulting in cell degranulation and release of pro-3 
inflammatory mediators.  The extent of effector cell activation is linked to allergen affinity, 4 
oligomeric state, valency and spacing of IgE binding epitopes on the allergen. While most of these 5 
observations come from studies utilising synthetic allergens, here we have used timothy grass 6 
pollen allergen Phl p 7 and birch pollen allergen Bet v 4 to study these effects.  Despite the high 7 
homology of these polcalcin-family allergens, Phl p 7 and Bet v 4 display different binding 8 
characteristics towards two human patient-derived polcalcin-specific IgE antibodies. We have 9 
used native polcalcin dimers and engineered multimeric allergens to test the effects of affinity and 10 
oligomeric state on IgE binding and effector cell activation. Our results indicate that polcalcin 11 
multimers are required to stimulate high levels of effector cell degranulation when using the 12 
humanised RBL-SX38 cell model, and that multivalency can overcome the need for high-affinity 13 
interactions. 14 
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Introduction 1 
The initiating event of an allergic immune response is the cross-linking by a multivalent allergen 2 
of IgE antibodies that are bound to their high-affinity receptor (FceRI) on the surface of effector 3 
cells, such as mast cells and basophils (1). Small amounts of multivalent allergen are sufficient to 4 
cross-link IgE-FceRI complexes on the effector cell surface and, on a time-scale of seconds to 5 
minutes, initiate the “early phase” of the allergic reaction.  This results in the rapid release of 6 
inflammatory mediators (e.g. histamines and leukotrienes) (1–4).  7 
Naturally occurring allergens are most commonly complex multivalent proteins. The timothy grass 8 
pollen allergen Phl p 5, despite its small size of 29 kDa, is highly allergenic and has multiple 9 
independent IgE epitopes (5). Similarly, the major peanut allergen Ara h 3 contains at least four 10 
distinct immunodominant epitopes on its surface (6). Allergens may also exist in multimeric forms 11 
and present identical epitopes. For example, the dimeric form of major birch pollen allergen Bet v 12 
1 is required for effective IgE cross-linking, whereas the monomeric Bet v 1 form does not trigger 13 
an allergic response in a murine model (7). Most allergens, such as Ole e 1 from olive tree (8) and 14 
house dust mite allergen Der p 2 from Dermatophagoides pteronyssinus (9, 10) exist in several 15 
variants (isoallergens). These isoallergen variations further contribute to the complexity of 16 
allergens, as multiple isoforms may be differentially recognised by the same monoclonal antibody 17 
(10). Similarly, there exists cross-reactivity between structurally homologous allergens from 18 
different sources, especially between food allergens and pollen (11, 12). 19 
Due to the complexity of naturally occurring allergens and the polyclonality of IgE antibodies 20 
generated against these allergens in vivo, researchers often employ simplified model systems using 21 
synthetic allergens to study the mechanisms of allergic reactions. One well-characterised system 22 
 5 
is the hapten/antibody pair, dinitrophenyl (DNP)/anti-DNP IgE. In these systems, small synthetic 1 
allergens are often conjugated to a carrier protein, such as bovine serum albumin (BSA) (13), or a 2 
synthetic scaffold (14–17), or incorporated into liposomes (18). Alternatively, artificial allergens 3 
have been generated by grafting IgE epitopes onto a scaffold protein in different numbers and 4 
spacings (19).  Use of rigid or flexible linkers of different lengths provided information about the 5 
optimal spacing of the epitopes for intermolecular and intramolecular cross-linking of IgE-FceRI 6 
complexes (20–25). Some systems incorporate more than one hapten into the model system, such 7 
as combining DNP and dansyl, as described in work by Handlogten et al. (16, 17). The use of such 8 
experimental model systems has allowed investigations of the importance of allergen valency, 9 
affinity, spacing and synergy in allergen-antibody interactions. However, it is generally understood 10 
that simplified model systems using small molecules as allergens may not fully reflect the 11 
complexity of naturally occurring allergens.  12 
Here we describe an antibody-allergen interaction model system, consisting of polcalcin allergens 13 
from pollen and patient-derived polcalcin-specific human IgE antibodies. Here termed HAPPIE 14 
(Human Anti-Phl p 7 Immunoglobulin E antibodies), these human antibodies were identified from 15 
single B cell clones and expressed recombinantly (26, 27); they have specificity for the timothy 16 
grass pollen allergen Phl p 7, a small 2-EF hand calcium-binding allergen from polcalcin family 17 
(28, 29). Recently, an X-ray crystal structure of the Fab fragment of HAPPIE1 (called 102.1F10 18 
in earlier studies) was solved in complex with the Phl p 7 allergen (30). In this study, we 19 
characterised the interactions between recombinantly expressed HAPPIE antibodies and polcalcin 20 
allergens, and this enabled us to assess the role of allergen affinity, valency and oligomeric state 21 
in effective IgE-binding and cross-linking on effector cells. 22 
 6 
Polcalcin allergens from different pollen sources, such as alder (Aln g 4), birch (Bet v 4) and olive 1 
(Ole e 3), share high sequence and structure similarity with Phl p 7 (31), and here we show that 2 
they display varying degrees of cross-reactivity to two HAPPIE antibodies. We have utilised these 3 
differences to study the role of allergen affinity in effective IgE-FceRI cross-linking on effector 4 
cells using the humanized rat basophilic leukemia (RBL-SX38) cell line (32), expressing human 5 
FceRI, as a basophil cell model. Previously, the effects of number and proximity of IgE binding 6 
sites on an allergen have been studied using an artificial allergen, generated by grafting IgE-7 
reactive Phl p 1 peptides onto the myoglobin molecule (19). Here, we have used monomeric 8 
polcalcin proteins, naturally occurring polcalcin dimers and engineered multivalent allergens to 9 
study the role of allergen valency, epitope spacing and flexibility in effective IgE binding and 10 
triggering of cell degranulation. 11 
Our results suggest that polcalcin multimers are required to stimulate high levels of basophil 12 
degranulation and that basophils respond most effectively to multimeric allergens with high 13 
affinity for IgE.  Further, a low affinity IgE antibody can still mediate effector cell activation, 14 
utilising the avidity effects of a polyvalent allergen.  The allergen-antibody model system we have 15 
established and the results presented here thus will contribute to a better understanding of the 16 
factors affecting allergen-IgE interactions and enable further elucidation of the mechanisms of the 17 
human allergic immune responses to these clinically relevant allergens. 18 
 7 
Methods 1 
Protein expression and  purification 2 
Recombinant allergens were expressed and purified as previously described (30). Stable HEK293F 3 
cell lines expressing full length HAPPIE1 and HAPPIE2 antibodies, as well as HAPPIE2-Fab, 4 
were produced using FuGene HD (Promega) as a transfection agent according to established 5 
protocols (33). In earlier work, HAPPIE1 and HAPPIE2 antibodies were called 1021F10 and 6 
CS09G6K, respectively (30). For IgE purification, an anti-IgE affinity column was prepared by 7 
conjugating the anti-IgE antibody Xolair (Novartis) onto NHS-activated Sepharose 4 Fast Flow 8 
pre-activated media (GE Healthcare Life Sciences) according to the manufacturer’s instructions. 9 
Recombinant IgE proteins were then purified using affinity chromatography. His-tagged 10 
HAPPIE2-Fab was purified using nickel affinity chromatography methods. All recombinant 11 
proteins were further purified using size exclusion chromatography using Superdex 75 Increase 12 
10/300 GL or Superdex 200 Increase 10/300 GL columns (GE Healthcare).  13 
Production of SA oligomeric allergens 14 
Purified recombinant Phl p 7 was conjugated via the sulfhydryl of residue Cys64 to ChromaLinkÔ 15 
Biotin Maleimide reagent (SoluLink), according to the manufacturer’s instructions. Biotin reagent 16 
molecule included a PEG3 linker, serving to reduce steric hindrance and provide orietational 17 
flexibility within the streptavidin-allergen complex. Unreacted biotin was removed by size 18 
exclusion chromatography and biotinylated Phl p 7 was then incubated with streptavidin (SA) 19 
(Sigma) at different molar ratios and then passed through a Superdex 200 Increase column (GE 20 
Healthcare) to separate streptavidin-Phl p 7 (SA-Phl p 7) complexes from unbound Phl p 7. 21 
Fractions containing SA-Phl p 7 were visualised using non-denaturing SDS PAGE to confirm the 22 
 8 
presence of the streptavidin-allergen complexes. A similar protocol was followed to produce 1 
multivalent Bet v 4 complexes. Site-directed mutagenesis was used to mutate an alanine residue 2 
(Ala71) in Bet v 4 to cysteine in the homologous position to residue cysteine 64 in Phl p 7. 3 
Mutagenic primers used were 5’-GGAGTTTACCGACTTTTGTCGTGCAAACCGTGG-3’ for 4 
forward and 5’-CCACGGTTTGCACGACAAAAGTCGGTAAACTCC-3’ for reverse primers.   5 
Distance calculations for epitope spacing in different SA-allergen dimer conformations were a 6 
summation of an allergen radius of gyration, PEG3 linker Flori radius (calculated as 0.7 nm) (34) 7 
and the distance between selected biotin molecules bound to streptavidin (measured using biotin 8 
bound streptavidin (PDB ID 1NDJ) structure as a template (35)). A full list of measurements is 9 
available in supplemental Table S3.  10 
Surface plasmon resonance 11 
SPR experiments were performed on a Biacore T200 instrument (GE Healthcare). The running 12 
buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 4 mM CaCl2, and 0.001% (v/v) Surfactant P-20) 13 
was the same for all experiments. All experiments were performed at 25 °C unless stated otherwise. 14 
Sensor chip surfaces were prepared by covalently coupling specific proteins using the well-15 
established amine coupling protocol (GE Healthcare). Experiments to study the thermodynamics 16 
of HAPPIE2’s interaction (Fab was used in these experiments) with Phl p 7 and Bet v 4 were 17 
performed at 5 °C, 15 °C, 25 °C and 35 °C. SPR data were analysed using BIAevalution software 18 
(GE Healthcare Life Sciences) and Origin 7 (OriginLab). In all cases standard double-referencing 19 
data subtraction methods were applied (36). Data fitting was performed using Origin 7 (OriginLab) 20 
or Python scientific computing library SciPy (version 0.18.1), with the scripts for curve fitting 21 
 9 
available at https://github.com/gintarebucaite/SPR_data_fitting.  Analysis of thermodynamic data 1 
was performed using a linear form of the van't Hoff equation (37). 2 
Cell culture 3 
The rat basophilic leukaemia (RBL) cell line expressing the a, b and g chains of human FceRI 4 
(RBL-SX38) was cultured in RBL media (DMEM supplemented with 10% FBS, 2 mM L-5 
glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin, and 500 μg/mL geneticin) in a 6 
humidified, 37 °C, 5% CO2 incubator. 7 
Cell degranulation assays 8 
The assay protocol for mast cell degranulation was adapted from Bax et al. (38). RBL-SX38 cells 9 
were plated in 96-well plates at 104 cells/well and incubated overnight at 37 °C, 5% CO2. The 10 
following day cells were sensitised with 200 ng/mL of IgE in RBL media (100 μL/well) for 24 h. 11 
Following washes with the assay buffer (Hank’s Balanced Salt Solution (HBSS) containing 1% 12 
bovine serum albumin), the allergen was added over a concentration range of 0.5 pM to 5 µM (100 13 
μL/well, diluted in the assay buffer). A polyclonal rabbit anti-human IgE antibody (Dako, A0094) 14 
was used as a positive control. Assay buffer with 1% Triton X-100 (100 μL/well) was used to lyse 15 
the cells and determine the maximum degranulation. Assay buffer on its own was used (100 16 
μL/well) as a negative control. Cells were incubated for 1 h at 37 °C and then 25 μL/well of the 17 
supernatant was transferred to a black 96-well plate for a b-hexosaminidase release assay using 4-18 
methylumbelliferyl N-acetyl-b-D-glucosaminide substrate (Sigma-Aldrich) as described 19 
previously (38). The percentage of maximum degranulation was calculated and data were analysed 20 
and plotted using Prism 7 (GraphPad). 21 
 10 
Results 1 
Polcalcin allergen binding to human patient-derived IgEs 2 
We recombinantly expressed and purified four polcalcin allergens (Aln g 4, Bet v 4, Ole e 3 and 3 
Phl p 7) and determined their binding affinities and kinetics to two monoclonal human patient-4 
derived Phl p 7-specific IgE antibodies (HAPPIE1 and HAPPIE2) using surface plasmon 5 
resonance (Fig. 1). Consistent with previous studies (30), we found that both anti-Phl p 7 IgE 6 
antibodies are cross-reactive with homologous polcalcin allergens from different pollen sources. 7 
Although there is both high sequence and structure similarities (31) among these four polcalcin 8 
allergens (sequence identities are between 67% and 91%), markedly different binding 9 
characteristics were observed. Phl p 7 and Ole e 3 bind to HAPPIE1 (Fig. 1 A and B; these data 10 
are summarised in Table 1) and HAPPIE2 (Fig. 1 E and F) with high affinity (the KD values for 11 
the interactions are as follows, for binding to HAPPIE1 and HAPPIE2, respectively: Phl p 7, 0.9 12 
nM and 0.11 nM; Ole e 3, 1.0 nM and 0.8 nM).  The allergens Aln g 4 and Bet v 4, although highly 13 
homologous to Phl p 7 (the Phl p 7 sequence identity is 68% with Aln g 4 and 67% with Bet v 4), 14 
cross-reacted less strongly with both HAPPIE1 (Fig 1 C and D) and HAPPIE2 (Fig. 1 G and H) 15 
(the KD values for Aln g 4 are 2320 nM and 390 nM; Bet v 4 are 4430 nM and 3430 nM, for 16 
binding to HAPPIE1 and HAPPIE2 respectively). Based on these observations, we performed 17 
further experiments using Bet v 4 and Phl p 7 as representative low-affinity and high-affinity 18 
allergens, respectively, allowing us to explore the role of allergen affinity in IgE binding and 19 
effector cell degranulation. 20 
 21 
 22 
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Thermodynamics of Bet v 4 and Phl p 7 binding to HAPPIE2 1 
Additional SPR experiments were performed to derive the thermodynamic parameters of Bet v 4 2 
and Phl p 7 binding to HAPPIE2.  Over a range of temperatures, from 5 oC to 35 oC, we measured 3 
binding kinetics and affinities of the allergen to the covalently immobilised HAPPIE2 Fab 4 
fragment.  For each temperature, a concentration binding series was performed (Fig. S1) and 5 
interaction kinetic parameters and affinities were extracted. The affinity of Phl p 7 for the 6 
HAPPIE2 Fab decreased with increasing temperature, and the Bet v 4 interaction with the 7 
HAPPIE2 Fab was largely temperature independent (Fig. S1).  A van't Hoff analysis of the 8 
temperature dependence of binding was performed (Fig. 2), which allows the extraction of 9 
enthalpic and entropic contributions to binding.  HAPPIE2 Fab's interaction with Phl p 7 showed 10 
favourable interactions for both enthalpy and entropy (ΔH = -36.4 kJ mol-1, -T ΔS = -19.7 kJ mol-11 
1), while the (weaker) interaction with Bet v 4 was dominated by a favourable entropy term (ΔH = 12 
-7.1 kJ mol-1, -T ΔS = -23.8 kJ mol-1).  It is not surprising that the cross-reactivity seen with Bet v 13 
4 is less enthalpically favourable than the Phl p 7 interaction; similarly to HAPPIE1, the HAPPIE2 14 
antibody was derived from a patient with grass pollen allergies, and this antibody likely underwent 15 
affinity maturation against the Phl p 7 antigen, optimising for non-covalent interactions with this 16 
target (30). Cross-reactivity towards Bet v 4 would be expected to have imperfect complementarity 17 
with the conserved but not identical Bet v 4 protein.  The Bet v 4 interaction would therefore be 18 
expected to be comprised of fewer hydrogen bonds and ionic interactions, and less optimal van 19 
der Waals interactions but would still be capable of solvent exclusion of a similar protein surface, 20 
resulting in a similar entropy term. Different thermodynamic signatures can be used to distinguish 21 
specific versus non-specific interactions; specific interactions tend to be enthalpically driven, 22 
while non-specific interactions tend to be entropically driven (39, 40).  23 
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Native polcalcin dimers trigger RBL-SX38 cell degranulation 1 
The family of polcalcin proteins have been shown to exist both as monomers and domain-swapped 2 
homodimers (41). Recombinantly expressed polcalcins can form monomers and intertwined 3 
dimers, and these oligomeric states can be separated using size-exclusion chromatography during 4 
the purification process (Fig. S2). To determine the capacity of naturally forming polcalcin dimers 5 
to cross-link IgE-FceRI complexes on the effector cell surface, b-hexosaminidase release was 6 
measured for RBL-SX38 cells sensitised with monoclonal Phl p 7-specific IgE and then stimulated 7 
with allergens in either monomeric or dimeric form (separated by size-exclusion chromatography) 8 
at concentrations ranging from 0.5 pM to 5 µM (Fig. 3). We have also produced monomeric 9 
polcalcin mutants stabilised by an internal disulfide bridge, which stabilises the monomer 10 
conformation, as described by Magler et al. (41). When RBL-SX38 cells were sensitised with 11 
either HAPPIE1 or HAPPIE2, no significant degranulation was detected when stimulated either 12 
wild-type monomer or disulfide stabilised monomeric allergens (Fig. 3). In previous experiments, 13 
monomeric Phl p 7 has been reported to activate HAPPIE1-sensitised basophils, and a 14 
superantigen-like mechanisms was proposed for this activity (30). However, in the current 15 
experiments the disulfide-stabilised monomeric Phl p 7 showed no capacity to crosslink HAPPIE1 16 
and trigger basophil degranulation (Fig. 3B). 17 
Low concentrations of native Phl p 7 dimer (Fig. 3 B and D), but not dimeric Bet v 4 (Fig. 3 A and 18 
C), triggered basophil degranulation when cells were sensitised with either HAPPIE1 or HAPPIE2. 19 
The native Bet v 4 dimer could not effectively cross-link receptor-bound HAPPIE1 (Fig. 3A), and 20 
only a very small amount of degranulation was observed for receptor-bound HAPPIE2 at the 21 
highest concentrations of Bet v 4 tested (Fig. 3C). We therefore designed further experiments to 22 
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test how effector cell sensitivity would change when stimulated with higher oligomeric state 1 
allergens.  2 
Multimeric allergen design and production 3 
Multivalent Bet v 4 and Phl p 7 allergens were engineered and produced to study the interplay 4 
between allergen valency and affinity in IgE binding and effector cell activation. The ultrahigh-5 
affinity streptavidin-biotin interaction was utilised to generate multimeric allergens. Biotin was 6 
site-specifically conjugated to the two allergens via the single free-sulfhydryl in each protein (at 7 
Cys64 in Phl p 7, and a cysteine residue introduced at the homologous position in Bet v 4 using 8 
site-directed mutagenesis) using a maleimide-biotin reagent. The biotin-maleimide reagent used 9 
in the reaction contained a flexible PEG3 linker and a UV-traceable chromophore, allowing rapid 10 
confirmation of the degree of biotinylation. Biotinylated allergens were then incubated at various 11 
concentrations with tetrameric streptavidin (SA) to form SA-allergen complexes (resulting 12 
complexes had highest possible valency of four biotinylated allergens bound per tetrameric SA 13 
(Fig. 4 B)) and the reaction was assessed using SDS PAGE (Fig. 4 A). The unbound biotinylated 14 
allergen was separated from the SA-polcalcin complexes using size-exclusion chromatography 15 
(Fig. 4 C). Fig. 4 summarises the approach used to produce SA-Bet v 4 complexes; an identical 16 
protocol was followed to generate SA-Phl p 7 multimers. Streptavidin-polcalcin complexes with 17 
different polcalcin/streptavidin ratios were also produced (Fig. 4 D and E), enabling study of the 18 
role of allergen valency in IgE binding and basophil degranulation. Streptavidin-polcalcin dimers 19 
and trimers, while distinct peaks in size-exclusion chromatography (Fig. 4 C and D), are 20 
heterogenous species due to the intrinsic asymmetry of the streptavidin tetramer (Fig. 4E), while 21 
monomers and tetramers are homogeneous.   22 
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Based on the radii of gyration calculated for the proteins used here (full details about estimated 1 
distances are available in supplemental Table S3), we estimate that the distances between the 2 
epitopes in engineered Bet v 4 multimers would range between 2.4 and 7.3 nm, which is close to 3 
the distances between epitopes observed in published Fab-allergen-allergen-Fab crystal structures, 4 
such as 4 nm in the Bos d 5 dimer structure (42) and 6.3 nm in the Bla g 2 dimer (43). Native 5 
polcalcin dimers would have a maximum diameter of around 3.0-3.2 nm, which is less than the 6 
suggested optimal distance of ~6 nm between epitopes as determined in synthetic allergen model 7 
systems  (24, 25). It would therefore be anticipated that engineered multimeric allergens would 8 
display improved IgE cross-linking when compared to native dimers. Additionally, the spacing 9 
between the IgE-binding epitopes on streptavidin-polcalcin multimers would not be great enough 10 
to cross-link both Fabs on a single IgE antibody (Fabs may be cross-linked by ligands of around 11 
11 to 15 nm (20, 44, 45)).  12 
Multimeric allergens demonstrate avidity in SPR 13 
We used SPR to determine whether increasing allergen valency in engineered polcalcin constructs 14 
results in avidity and consequently more efficient binding by measuring how Bet v 4 binding to 15 
HAPPIE1 changed with increased valency. For this, a "high-density" SPR surface was prepared. 16 
HAPPIE1 IgE was captured on a sensor surface at ~1000 RU, a density sufficiently high to allow 17 
observation of multivalent effects. Monomeric Bet v 4 binding to HAPPIE1 reached equilibrium 18 
rapidly and the allergen dissociated rapidly from the antibody surface (Fig. 5 A).  Native Bet v 4 19 
dimers showed moderate avidity effects (Fig. 5 B), characterised by slightly slower off-rates. 20 
Engineered Bet v 4 dimers and trimers, however, dissociated from the IgE surface markedly more 21 
slowly, indicating that increased valency resulted in tighter binding due to avidity effects (Fig. 5 22 
C and D). Similar experiments were performed with Bet v 4 constructs binding to HAPPIE2, and 23 
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Phl p 7 constructs binding to HAPPIE1 and HAPPIE2 captured on the sensor surface.  In all 1 
experiments, we observed slower dissociation rates at increased allergen valency due to avidity 2 
effects. In higher oligomeric state complexes, dissociation at one of the binding sites is more likely 3 
to be followed by reassociation at another binding site rather than complete dissociation of the 4 
complex (46). We next performed effector cell degranulation assays using multivalent SA-5 
allergens to test whether the increase in valency would have an effect on the binding and cross-6 
linking of IgE-receptor complexes on effector cells.  7 
RBL-SX38 degranulation by multimeric polcalcin allergens 8 
We used the multivalent polcalcin allergens in RBL-SX38 degranulation assays to investigate the 9 
role of allergen valency in effective cross-linking of IgE-FceRI complexes on the surface of the 10 
effector cells. When RBL-SX38 cells were saturated with either HAPPIE1 or HAPPIE2, high 11 
levels of cellular degranulation, as measured by b-hexosaminidase release, were observed when 12 
stimulated with either Bet v 4 or Phl p 7 multimers (Fig. 6). EC50 values are summarised in Table 13 
2.  14 
Similar levels of degranulation were triggered by bivalent (EC50 = 0.5 nM and 0.7 nM for cells 15 
sensitised with HAPPIE1 and HAPPIE2, respectively), trivalent (HAPPIE1 EC50 = 0.4 nM; 16 
HAPPIE1 EC50 = 0.7 nM (HAPPIE2)) or tetravalent Phl p 7 (HAPPIE1 EC50 = 0.7 nM; HAPPIE1 17 
EC50 = 0.3 nM) constructs (Fig 6 B and D). For all of these constructs there were no statistically 18 
significant differences in EC50 values; all the different Phl p 7 multimers cross-linked and activated 19 
RBL cells at subnanomolar concentrations.   20 
In contrast, we observed that the oligomeric state does affect effector cell sensitivity when cells 21 
are primed with IgE antibodies with low affinity for the allergen. Tetravalent and trimeric Bet v 4 22 
 16 
triggered significant levels of basophil degranulation at lower concentrations than dimeric 1 
complexes (Fig 6 A and C).  (EC50 = 0.3 nM (tetramer) vs EC50 = 1.8 nM (dimer), **p £ 0.01; 2 
EC50 = 0.6 nM (trimer) vs EC50 = 1.8 nM (dimer), **p £ 0.01; EC50 = 0.3 nM (tetramer) vs EC50 3 
= 0.6 nM (trimer) when cells were sensitised with HAPPIE1, n.s.; EC50 = 0.2 nM (tetramer) vs 4 
EC50 = 1.5 nM (dimer), ***p £ 0.001; EC50 = 0.3 nM (trimer) vs EC50 = 1.5 nM (dimer), **p £ 5 
0.01; EC50 = 0.2 nM (tetramer) vs EC50 = 0.3 nM (trimer) when cells were sensitised with 6 
HAPPIE2 and stimulated with Bet v 4 complexes, n. s.). This suggests that allergen valency can, 7 
under some circumstances, play an important role in effective IgE-receptor cross-linking, and that 8 
an antibody’s low affinity for allergen can be overcome by avidity effects.   9 
These degranulation experiments using streptavidin-polcalcin complexes have also suggested the 10 
role epitope spacing may play in the effective receptor cross-linking on the cell surface. Engineered 11 
Bet v 4 dimers (Fig. 6 A and C) were more potent in degranulation assays than native Bet v 4 12 
dimers (Fig. 3 A and C), which is clearly illustrated when the potency of these allergens is 13 
compared directly (Fig. S4). RBL-SX38 cells were activated by native Bet v 4 dimers only at high 14 
concentrations (**p £ 0.01, HBSS vs 2.5 µM native Bet v 4 dimer, estimated EC50 = 2.9 µM) and 15 
when primed with HAPPIE2 but not HAPPIE1. SA-Bet v 4 dimers, however, triggered high levels 16 
of degranulation at more than a thousand-fold lower concentrations when compared to native 17 
dimers and stimulated RBL-SX38 cells sensitised with either HAPPIE1 or HAPPIE2 (estimated 18 
EC50 = 1.8 nM and 1.5 nM for cells sensitised with HAPPIE1 or HAPPIE2, respectively).  19 
The number of available epitopes is the same in the engineered Bet v 4 dimer as in the native 20 
dimeric Bet v 4; therefore, it is likely that it is the difference in spacing between epitopes that 21 
results in different effector cell activation profiles for these two different dimeric structures.  22 
 17 
In the polcalcin-streptavidin dimer, distances between polcalcin epitopes are greater, and there is 1 
potentially greater orientational flexibility for these molecules, due to the biotin-maleimide-PEG3 2 
linker (with a calculated Flory radius of ~0.7 nm (34)). Based on measurements of the dimeric Bet 3 
v 4 model generated by SWISS-MODEL homology  modelling server (47–49) and models of 4 
monomeric Bet v 4 (50) bound to tetrameric streptavidin (35), we can estimate the average 5 
distances between polcalcin epitopes.  Engineered polcalcin-streptavidin dimers are heterogenous 6 
and can exist in both cis- or trans- conformations (Fig. 4E), but all possible conformations would 7 
likely have larger distances between epitopes than native Bet v 4 dimer. For example, the longest 8 
distance between two epitopes recognised by an antibody on a native polcalcin would be about 9 
3.0-3.2 nm. In the engineered polcalcin dimer, those epitopes would be on average separated by 10 
about 4.1 nm in cis-conformation, and by > 6 nm in either of the trans- conformations.  11 
 18 
Discussion 1 
The results presented here describe an antibody-allergen interaction model system that can be used 2 
to study how certain allergen properties, such as affinity towards the IgE antibody or the allergen’s 3 
oligomeric state, affect the extent of effector cell activation as a result of IgE-FceRI complex cross-4 
linking. Here we utilised monoclonal human patient-derived IgE antibodies against pollen 5 
allergens as model antibodies, and we have used recombinant Phl p 7 from timothy grass pollen 6 
and its homologues from different pollen sources, such as alder, birch and olive tree, as 7 
representative allergens.  8 
Most of the currently used allergen-antibody model systems utilise small haptens, such as DNP 9 
and dansyl, as allergens, where the hapten is usually conjugated to a carrier protein, such as BSA, 10 
or a scaffold (13–18). Haptens are most commonly conjugated to BSA through reactive amine 11 
groups, consequently it is not always straightforward to control valency and allergen spacing. In 12 
model systems where haptens are conjugated to a chemically synthesised scaffold (as described 13 
by Handlogten et al. (15)), these problems can be overcome. But such models still use small 14 
synthetic molecules as haptens, while most naturally occurring allergens are complex proteins. 15 
Further, the IgE antibodies used in most experimental models are usually of non-human origin 16 
(51). The HAPPIE antibodies used in this study are recombinantly-expressed, monoclonal human 17 
patient-derived antibodies with matched heavy and light chains (26). Finally, the human origin of 18 
the antibodies enabled us to perform functional assays with a cell line expressing a human FceRI 19 
on the effector cell surface, whereas the cell line of choice in most similar experiments modelling 20 
the human allergic response is RBL-2H3, which expresses rat FceRI, and mouse antibodies are 21 
used. The HAPPIE/polcalcin allergen system offers, we believe, a model system that has the 22 
potential to more closely mimic human allergic reactions than many existing model systems.  23 
 19 
Some previous studies have concluded that bivalent allergens trigger low levels of mast cell 1 
degranulation even in the instances when the allergen affinity is high (17). In contrast, synthetic 2 
trivalent ligands have been shown to be highly potent in cross-linking IgE-FceRI complexes (23, 3 
52).  However from our studies, as well as others (e.g. the dimeric Bet v 1 (7) and Hev b 8 (54) 4 
allergens), it is clear that dimeric allergens are fully capable of triggering a robust degranulation 5 
response. Dimeric allergens, after all, can theoretically generate large aggregates of cell surface 6 
IgE molecules via intermolecular interactions of the bivalent antibody molecules (19). But not all 7 
dimeric allergens will do this efficiently.  Dimeric allergens whose structures permit bivalent 8 
intramolecular interactions (i.e., with the two Fabs within an IgE molecule), or allergens that 9 
favour bicyclic IgE-FceRI complex dimers to form, result in very inefficient mast cell activation 10 
(20, 21, 55).  And, as we show in this work, bivalent allergens with low affinities and fast off-rates 11 
may result in only transient IgE crosslinking, insufficient for cellular activation. 12 
Our study demonstrates that, under some circumstances, low-affinity allergens can trigger cell 13 
degranulation without the presence of high-affinity binding sites. Previous studies support the 14 
importance of low affinity epitopes when presented together with high-affinity epitopes in effector 15 
cell activation (10, 17, 51). Here we show that IgE-FceRI complexes can be efficiently cross-16 
linked with low affinity allergens alone. High levels of effector cell degranulation were observed 17 
when HAPPIE-sensitised cells were stimulated with multivalent Bet v 4 constructs. 18 
While the native Bet v 4 dimer triggered low levels of degranulation and showed only a small 19 
amount of enhanced binding due to avidity in the SPR binding experiments (Fig. 5), dimeric 20 
streptavidin-Bet v 4 complexes were potent allergens and displayed marked increased avidity in 21 
the SPR experiments. This confirms that the spacing and flexibility of IgE-binding epitopes also 22 
play a role in efficient IgE-FceRI cross-linking and initiation of signalling cascade leading to cell 23 
 20 
degranulation (52, 56). While a previous study using artificial allergens has concluded that placing 1 
IgE epitopes in close proximity increases allergen potency (19), using streptavidin as a scaffold 2 
and a flexible PEG3 linker to increase the spacing between IgE epitopes resulted in higher allergen 3 
potency in our model system. This may have resulted from enhanced availability of IgE-binding 4 
sites due to the incorporation of a flexible linker between the streptavidin scaffold and the allergen 5 
itself, allowing some movement and repositioning of multiple epitopes in respect to each other.  6 
In summary, here we describe a model allergen-antibody system utilising patient-derived IgE 7 
antibodies and the protein allergens to which patients react, and demonstrate the importance of 8 
allergen affinity, oligomeric state and epitope spacing in IgE binding and mast cell degranulation.  9 
 10 
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Tables 1 
Allergen Antibody KD ± SD (nM) 
Aln g 4 
HAPPIE1 2320  ±  50 
HAPPIE2 390 ± 110 
Bet v 4 
HAPPIE1 4430 ± 1400 
HAPPIE2 3430 ± 770 
Ole e 3 
HAPPIE1 1.0 ± 0.45 
HAPPIE2 0.8 ± 0.14 
Phl p 7 
HAPPIE1 0.9 ± 0.1 
HAPPIE2 0.11 ± 0.01 
Table 1. Summary of selected polcalcin binding affinity values to HAPPIE1 and HAPPIE2 2 
antibodies. Data given as ±SD, experiments were run in duplicate. 3 
EC50 ± SD (nM) Bet v 4 Phl p 7 
 HAPPIE1 HAPPIE2 HAPPIE1 HAPPIE2 
Dimer 1.8 ± 0.1 1.5 ± 0.1 0.5 ± 0.2 0.7 ± 0.1 
Trimer 0.6 ± 0.2 0.3 ± 0.1 0.4 ± 0.1 0.7 ± 0.3 
Tetramer 0.3 ± 0.04 0.2 ± 0.06 0.7 ± 0.3 0.3 ± 0.1 
Table 2. Estimated EC50 values for dimeric, trimeric and tetrameric polcalcin potency to 4 
trigger RBL-SX38 degranulation. Data shown are the averages ±SD of at least three experiments 5 
with three biological replicates per experiment.  6 
 30 
Figures1 
 2 
Fig.1 Polcalcin allergen binding to HAPPIE1 (A-D) and HAPPIE2 (E-H). Fusion protein of 3 
IgG4 Fc and the soluble form of FcεRI receptor (sFcεRIα) (57) was immobilized on an SPR sensor 4 
chip and IgE molecules were captured on the chip via the immobilized sFcεRIα; allergens were 5 
then flowed over the IgE surface over a range of concentrations. Allergens were injected using a 6 
two-fold dilution series, with the highest concentrations as follows: 2000 nM for Aln g 4 binding 7 
to HAPPIE1; 2000 nM for Aln g 4 binding to HAPPIE2; 2000 nM  of Bet v 4 for binding to 8 
HAPPIE1; 4000 nM  of Bet v 4 for binding to HAPPIE2; 62.5 nM for Ole e 3 binding to both 9 
HAPPPIE1 and HAPPIE2; 100 nM for Phl p 7 for binding to both HAPPIE1 and HAPPIE2.10 
 31 
 1 
Fig. 2  The thermodynamic parameters of Phl p 7 (triangles) and Bet v 4 (squares) interaction 2 
with HAPPIE2 Fab. SPR binding experiments were performed at temperatures of 5, 15, 25 and 3 
35 oC.  Data are shown as van't Hoff plots and the enthalpic contributions to binding were extracted 4 
using a linear van't Hoff analysis (58) (dashed lines show linear fit of the data). HAPPIE2 Fab/Phl 5 
p 7 interaction:  ΔH = -36.4 kJ mol-1, -TΔS = -19.7 kJ mol-1, ΔG = -56.1 kJ mol-1; HAPPIE2 6 
Fab/Bet v 4 interaction: ΔH = -7.1 kJ mol-1, -TΔS = -23.8 kJ mol-1, ΔG = -30.9 kJ mol-1.7 
 32 
 1 
Fig. 3. RBL-SX38 cell degranulation assays with recombinant Bet v 4 and Phl p 7 monomeric 2 
and dimeric proteins. RBL-SX38 were sensitised with HAPPIE1 (A and B) or HAPPIE2 (C and 3 
D) and then stimulated with wild-type monomer or native dimer Bet v 4 (A and C), or disulfide 4 
stabilised monomer, wild-type monomer or native dimeric versions of Phl p 7 (B and D). Data 5 
were normalised as the percentage of maximum degranulation (%max degran; determined by cell 6 
lysis with 1% Triton-X100) and fitted to determine the EC50 values. One-way ANOVA, followed 7 
by Tukey’s multiple comparison tests were used to determine the statistical significance between 8 
the levels of b-hexosaminidase release when stimulated with wild-type monomers, disulfide 9 
stabilised monomers or native dimeric allergens when compared to background levels of 10 
degranulation (HBSS only); statistical tests are based on the highest concentrations of allergen 11 
tested (****p < 0.0001). Data shown are the averages ±SD of at least three experiments with three 12 
biological replicates per experiment.  13 
 33 
 1 
Fig. 4. Multimeric allergen production and purification using streptavidin as a scaffold. 2 
Streptavidin was incubated with biotinylated allergen to yield multivalent allergen complexes (A); 3 
a model of the tetrameric streptavidin-allergen complex is shown in (B) allergen is in dark blue, 4 
and streptavidin monomers are in black, grey, teal and light cyan. The streptavidin-allergen 5 
mixture was purified using size-exclusion chromatography and the eluted analyte was detected by 6 
measuring the absorbance at 280 nm and 354 nm (C). Individual peaks were visualised using SDS 7 
PAGE (D) and possible multimeric configurations (tetramer, trimer, cis- and trans-dimers) are 8 
shown in (E).   9 
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 1 
Fig. 5. SPR binding analysis of wild-type Bet v 4 (A), native Bet v 4 dimer (B), dimeric 2 
streptavidin-Bet v 4 (C) and trimeric streptavidin-Bet v 4 complexes (D) to HAPPIE1 3 
captured on the sensor surface. Wild-type (A) and native dimeric (B) Bet v 4 was injected over 4 
HAPPIE1 sensor surface in a two-fold dilution series with a highest concentration of 2000 nM. 5 
(C) and (D) Engineered Bet v 4 dimers (C) and trimers (D) were added to HAPPIE1 over a range 6 
of two-fold dilution series concentrations, starting with 200 nM as the highest concentration.   7 
 35 
 1 
Fig. 6. Degranulation of RBL-SX38 cells sensitised with HAPPIE1 (A and B) or HAPPIE2 2 
(C and D) and stimulated with multimeric variants of Bet v 4 (A and C) or Phl p 7 (B and 3 
D). Responses for cells stimulated with wild-type monomeric proteins is replicated from Figure 3 4 
and included for comparison purposes. Data were normalised as the percentage of maximum 5 
degranulation (cell lysis with 1% Triton-X100). Data shown are the averages ±SD of at least three 6 
experiments with three biological replicates per experiment. 7 
